Stifel Upgrades Tandem Diabetes Care to Buy, Price Target is $26
Stifel has upgraded Tandem Diabetes Care to a 'Buy' rating with a price target of $26 per share.
Stocks · News reference
Tandem Diabetes Care has received Health Canada approval for a license amendment for its t:slim X2 insulin pump, expanding its indications and sensor compatibility.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Stifel has upgraded Tandem Diabetes Care to a 'Buy' rating with a price target of $26 per share.
FDA clears Tandem Diabetes Care's Tandem Mobi as the first tubeless automated insulin delivery system with seven-day wear launching in 2027.
Tandem Diabetes Care announced U.S. FDA clearance for the Tandem Mobi system, enabling it to function as a tubeless automated insulin delivery system with up to seven days of wear.
Filed: 2026-11-13 AccNo: 0001438133-26-000148 Size: 140 KB Item 8.01: Other Events
Barclays maintained its Equal-Weight rating on Tandem Diabetes Care while increasing the price target from $18 to $20.